Fungal Infection Treatment Guidelines

Introduction to Treatment

The British Journal of Dermatology recommends considering compliance issues, suboptimal absorption, organism insensitivity, or reinfection if treatment failure occurs, and if clinical improvement but positive mycology, continue current therapy for 2-4 more weeks 1
The British Journal of Dermatology suggests switching to second-line therapy if no clinical improvement is observed 1

The American Academy of Dermatology recommends topical terbinafine 1% cream applied twice daily for 1-2 weeks as the first-line treatment for tinea pedis due to its superior efficacy and shorter treatment duration compared to other antifungal agents 1, 2
Ciclopirox olamine 0.77% cream/gel is also recommended as a first-line treatment for uncomplicated cases, applied for 4 weeks 2

The British Journal of Dermatology recommends oral itraconazole 100 mg daily for 4 weeks as a second-line therapy option 1
Oral terbinafine 250 mg is also an option for second-line treatment, with faster clinical resolution than topical treatments and similar efficacy to 4 weeks of clotrimazole 1% cream 2

Diabetic patients require more aggressive treatment and careful monitoring due to higher risk of complications and secondary bacterial infections, with a moderate strength of evidence 3, 1
Immunocompromised patients may need longer treatment courses and closer monitoring for treatment response, although the strength of evidence is limited 2, 3
Athletes may benefit from preventive measures including regular application of antifungal powders to shoes and feet, based on expert opinion 2

Hygiene measures such as wearing well-fitting shoes, changing socks daily, and applying antifungal powders can help prevent reinfection, with a moderate strength of evidence 3, 2
Applying foot powder after bathing can reduce infection rates from 8.5% to 2.1%, and thorough drying between toes, daily changes of socks, and periodic cleaning of footwear can help prevent recurrence 2
Treating all infected family members simultaneously can help prevent reinfection, with a moderate strength of evidence 3
Inadequate treatment duration and neglecting environmental factors can lead to recurrence, with a moderate strength of evidence 2, 3
Risk factors for tinea pedis include male gender, athletes, obesity, and diabetes, with a moderate strength of evidence 2

Topical treatments:
Oral treatments:
Monitor for hepatotoxicity or neutropenia with oral terbinafine, and be aware of potential rare adverse effects with other treatments, with a high strength of evidence 2